ANGIOTENSIN II, IGF-1 AND SKELETAL MUSCLE ATROPHY
血管紧张素 II、IGF-1 和骨骼肌萎缩
基本信息
- 批准号:8960378
- 负责人:
- 金额:$ 36.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-12-01 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Cachexia is a major complication of chronic diseases such as heart failure, kidney failure and cancer. In these conditions the renin-angiotensin system (RAS) is often activated. We have shown that Angiotensin II (Ang II) induces skeletal muscle wasting, while Insulin-like growth factor 1 (IGF-1) prevents it. Ang II disrupts insulin and
IGF-1 signaling, induces mitochondrial dysfunction, depletes muscle ATP, and inhibits 5'-Adenosine Monophosphate Activated Protein Kinase (AMPK) signaling, preventing the normal response to energy depletion. Activation of AMPK with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) restores energy balance and prevents Ang II wasting, indicating that AMPK plays a critical role in Ang II effects on skeletal muscle. Ang II also reduces the regenerative capacity of skeletal muscle following injury by depleting the muscle stem cell (MuSC) compartment, likely via AT1a receptor (AT1aR) mediated inhibition of Notch signaling. Muscle specific overexpression of IGF-1 activates AMPK, increases MuSC, and prevents Ang II-induced wasting, implicating AMPK and MuSC as key points of convergence for the opposing effects of Ang II and IGF- 1 in muscle. The long-term objectives of this project are to understand how Ang II alters skeletal muscle biology and how IGF-1 exerts its protective effects against Ang II-induced wasting; we will achieve these goals through three specific aims: Specific Aim 1. To demonstrate that impairment of energy balance and AMPK signaling mediate ANG II-induced skeletal muscle atrophy and to determine the mechanisms involved. We will use Ang II infusion with skeletal muscle specific AT1aR-/- mice, AMPK kinase dead (AMPK- KD) mice, Akt-/- mice, and constructs overexpressing constitutively active AMPK or Akt to examine whether the negative effects of Ang II on energy balance are mediated by alterations in AMPK and/or Akt signaling, and to ascertain the mechanisms of AICAR mediated rescue. We will also study human skeletal muscle tissue samples. Specific Aim 2: To demonstrate that Ang II induced insulin/IGF-1 resistance and dysregulation of glucose and protein metabolism are prevented by IGF-1 activation of AMPK. We will utilize AMPK-KD mice, MLC-IGF-1 mice (muscle specific IGF-1 transgenics), muscle specific IGF-1R-/- mice to assess effects of Ang II on insulin/IGF-1 signaling, to examine if rescue effects of IGF-1 are AMPK-dependent and study the effects of AICAR. Specific Aim 3: To demonstrate that Ang II and IGF-1 regulate muscle stem cells and, via this mechanism, alter muscle regeneration. We will use human tissue samples, MLC-IGF-1 mice, AT1aR-/- mice, Myf5LacZ/+ mice and the cardiotoxin-injury model to examine mechanisms whereby Ang II inhibits and IGF-1 stimulates muscle regeneration. Our results will provide key insights into mechanisms whereby Ang II impairs skeletal muscle metabolism, depletes MuSC and inhibits regeneration; as well as insights into novel effects of IGF-1 on skeletal muscle. These findings will allow development of innovative therapies to treat cachexia in chronic conditions in which the RAS is activated.
描述(由申请人提供):恶病质是慢性疾病如心力衰竭、肾衰竭和癌症的主要并发症。在这些情况下,肾素-血管紧张素系统(RAS)经常被激活。我们已经证明血管紧张素II (Ang II)诱导骨骼肌萎缩,而胰岛素样生长因子1 (IGF-1)阻止它。Ang II破坏胰岛素和
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PATRICE DELAFONTAINE其他文献
PATRICE DELAFONTAINE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PATRICE DELAFONTAINE', 18)}}的其他基金
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
7339832 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
8386880 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
7211258 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
8521341 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
7762718 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
血管紧张素 II、IGF-1 和骨骼肌萎缩
- 批准号:
7565948 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Insulin-like Growth Factor-1 and Atherosclerosis
胰岛素样生长因子-1 与动脉粥样硬化
- 批准号:
8575338 - 财政年份:2002
- 资助金额:
$ 36.12万 - 项目类别:
Insulin-Like Growth Factor-1 and Atherosclerosis
胰岛素样生长因子 1 与动脉粥样硬化
- 批准号:
7661380 - 财政年份:2002
- 资助金额:
$ 36.12万 - 项目类别:
Insulin-like Growth Factor-1 and Atherosclerosis
胰岛素样生长因子-1 与动脉粥样硬化
- 批准号:
8770038 - 财政年份:2002
- 资助金额:
$ 36.12万 - 项目类别:
Insulin-Like Growth Factor-1 and Atherosclerosis
胰岛素样生长因子 1 与动脉粥样硬化
- 批准号:
6573017 - 财政年份:2002
- 资助金额:
$ 36.12万 - 项目类别:
相似国自然基金
药用植物华泽兰中改善II型糖尿病并发抑郁症活性先导化合物的挖掘及其作用机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
脂肪干细胞外泌体调节Bax/BAK1-caspase-3/caspase8信号轴影响II型肺泡上皮细胞衰老在脓毒症肺损伤中的作用及机制
- 批准号:MS25H010004
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
1 类新药研发后补助(治疗用生物制品 1 类 MG-K10 人源化单抗注射液、II 期临床试验)
- 批准号:2025JK2095
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
1 类新药研发后补助(治疗用生物制品 1 类MG-ZG122 人源化单抗注射液、II 期临床试验)
- 批准号:2025JK2097
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
黏土矿物结构Fe(II)跨界面驱动氧化铁结合态有机质释放和转化机制
- 批准号:2025JJ50205
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
NIR-II荧光内镜辅助胰腺癌术中肿瘤活性评估的可视化研究
- 批准号:2025JJ50653
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
整合素β5调控TGFβ II型受体细胞内转
运促进胃癌转移的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
有序组装型NIR-II荧光探针的构建及疾病辅助诊断应用
- 批准号:2025JJ40014
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
αvβ3整合素靶向有机探针用于NIR-II FL/MRI双模态成像引导的三阴性乳腺癌光热治疗研究
- 批准号:2025JJ81013
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
全钒液流电池负极V(II)/V(III)电化学氧化还原的催化机理研究
- 批准号:2025JJ50094
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
IGF-II regulates lung fibrosis in scleroderma
IGF-II 调节硬皮病肺纤维化
- 批准号:
10171618 - 财政年份:2020
- 资助金额:
$ 36.12万 - 项目类别:
IGF-II regulates lung fibrosis in scleroderma
IGF-II 调节硬皮病肺纤维化
- 批准号:
10027971 - 财政年份:2020
- 资助金额:
$ 36.12万 - 项目类别:
IGF-II regulates lung fibrosis in scleroderma
IGF-II 调节硬皮病肺纤维化
- 批准号:
10620791 - 财政年份:2020
- 资助金额:
$ 36.12万 - 项目类别:
IGF-II regulates lung fibrosis in scleroderma
IGF-II 调节硬皮病肺纤维化
- 批准号:
10402939 - 财政年份:2020
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF Topic 090, Phase II, Devices to Close Ductus Arteriosus in Premature Infants IGF::OT::IGF
IGF::OT::IGF 主题 090,第二阶段,早产儿动脉导管闭合装置 IGF::OT::IGF
- 批准号:
9581252 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF - MODIFICATION 08: The purpose of this modification is to fund support services for Technical Assistance to the SBIR Phase II Awardees (Under option year 3). The period of performance i
IGF::OT::IGF - 修改 08:此修改的目的是为 SBIR 第二阶段获奖者的技术援助支持服务提供资金(在选项第 3 年下)。
- 批准号:
9594244 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
- 批准号:
9576448 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF TASK ORDER 13 - SELF II
IGF::OT::IGF 任务顺序 13 - 自我 II
- 批准号:
10027075 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF: SBIR Phase II, Topic 326: Development of Novel Therapeutic Agents that Target Cancer
IGF::OT::IGF:SBIR II 期,主题 326:针对癌症的新型治疗药物的开发
- 批准号:
9569000 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:
IGF::OT::IGF TASK ORDER 13 - SELF II
IGF::OT::IGF 任务顺序 13 - 自我 II
- 批准号:
10094129 - 财政年份:2017
- 资助金额:
$ 36.12万 - 项目类别:














{{item.name}}会员




